OMNICELL INCOMCL
ASignal's systematic analysis rates OMCL as Neutral.
Reflects the latest available analysis · analyzed Sep 14, 2026
The case on OMCL
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Free cash flow of $134.18M indicates strong cash generation
- Low debt-to-equity ratio of 0.15x suggests solid financial health
- Current ratio of 1.64x reflects adequate short-term liquidity
- Forward P/E of 16.03x is reasonable relative to growth expectations
- Significant year-over-year earnings growth of 333.3%
- RSI near neutral at 43.5, but price below both SMA20 and SMA50
- Negative MACD histogram suggests weakening momentum
- High PEG ratio of 15.40x indicates potential overvaluation relative to growth
- Low return on equity (3.06%) and return on assets (1.52%)
- Profit margin of 3.14% is thin for the healthcare sector
See the full verdict on OMCL
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes OMCL
Most investors never get a second opinion, let alone several. ASignal runs OMCL past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.